<DOC>
	<DOC>NCT00241475</DOC>
	<brief_summary>To evaluate activity of gefitinib in subjects with relapsed prostate cancer by estimating PSA response rate at study closure</brief_summary>
	<brief_title>Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Relapsed prostate cancer after prostatectomy or radiotherapy PSA levels below 10 ng/mL Lymph node negative Metastasis negative Withdrawal of hormone therapy at least 6 months before entry into the study Written informed consent Metastatic disease Hormonal treatment 6 months before study entry Concomitant radiotherapy, surgery and/or chemotherapy ILD</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Cancer of the Prostate</keyword>
</DOC>